瑞舒伐他汀对急性冠脉综合征患者炎症和细胞因子以及心血管事件的影响

摘要

Objective:To explore the clinical effect of rosuvastatin on inflammatory factors and cytokines in patients with acute coronary syndrome (ACS). Methods:168 cases of ACS were divided into Atorvastatin (56 cases),rosuvastatin 10 mg group (56 ca-ses) and 20 mg group (56 cases). The plasma levels of inflammatory factors and cytokines were measured,and the occurrence rate of cardiovascular events were observed. Results:The levels of hs-CRP,TNF-a,and IL-6 in 20 mg group and in 10 mg group were signifi-cantly lower than those before treatment (P<0. 05),and it was the lowest in 20 mg group among three groups. Besides,the levels of VEGF and VCAM-1 in 20 mg group and 10 mg group were also significantly lower. The incidence of serious cardiovascular events in three groups had no difference after the treatment. Conclusion:Rosuvastatin can decrease the plasma levels of inflammatory factors and cytokines,reducing inflammation and stabilizing atherosclerotic plaque,thereby,reducing the incidence of serious cardiovascular event, and improving the situation of patients with ACS.%目的：：探讨瑞舒伐他汀对急性冠脉综合征( acute coronary syndrome,ACS)患者炎症因子和细胞因子的影响。方法：将168例ACS患者随机分为三组,阿托伐他汀20 mg组56例、瑞舒伐他汀10 mg组56例和瑞舒伐他汀20 mg组56例,对比各组治疗前后血清中炎症因子和细胞因子水平,并观察心血管事件(再发心绞痛、非致死性心肌梗死和心源性死亡)发生率。结果：与治疗前相比,三组患者治疗后在超敏C反应蛋白(hs-CRP)、血清肿瘤坏死因子-a(TNF-a)和白细胞介素6(IL-6)水平方面均明显低于治疗前(均P<0.05),且瑞舒伐他汀20 mg组显著低于其他两组(均P<0.05)；三组患者在细胞因子VEGF和VCAM-1水平方面均显著降低(均P<0.05),且瑞舒伐他汀20 mg组显著低于其他两组(均P<0.05)；三组患者治疗后心血管事件发生率没有明显差异(P>0.05)。结论： ACS患者服用瑞舒伐他汀可降低炎症因子和细胞因子的水平,减轻炎症反应并能稳定动脉粥样斑块,且这种作用与剂量正相关,对改善ACS患者的病情有益。